Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Biomarkers For Response To Nivolumab In Head and Neck Squamous Cell Carcinoma

NCT03652142 is registered in ClinicalTrials.gov with Attikon Hospital as lead sponsor.

NCT NCT03652142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03652142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Biomarkers For Response To Nivolumab In Head and Neck Squamous Cell Carcinoma
Lead sponsor
Attikon Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2018
Completion date
May 1, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dna damage, dna double strand break, hnscc